For its third fiscal quarter (ending September 30), Cytokinetics Inc (NASDAQ: CYTK) has reported a 1% increase in E.P.S. from $-1.35 a year ago to $-1.36 in the current quarter. For the latest four quarters through September 30, E.P.S. were $-5.38 versus $-5.52 for the same period a year ago — a decline of -3%.
Recent Price Action
On 11/6/24, Cytokinetics Inc (NASDAQ: CYTK) stock enjoyed a very large increase of 5.7%, closing at $55.50. Moreover, unusually high trading volume at 199% of normal accompanied the advance. The stock has been weak relative to the market over the last nine months but has risen 7.7% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, CYTK is expected to be a major Value Eraser.
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment